GET DAILY SIGNALSOrthoPediatrics (KIDS): Can the Stock Reach a $37 Target?
Key Takeaways
- The central target of $37 reflects the average of the two current analyst price targets that sit above the latest market price, not a full consensus figure.
- Across eight verified analyst targets, the range is $27 to $38, with an overall mean of roughly $30.75 — essentially at or below the recent share price.
- With shares recently near $30.87, reaching $37 would require an advance of about 20%, a substantial move.
- Record third-quarter revenue, a raised full-year outlook, and an expanding pediatric product portfolio are the strongest supporting factors.
- The biggest risks are a valuation that has already rerated sharply, continued net losses, and analyst targets that have not kept pace with the rally.
- For more context on this ticker, explore the Major News, Today's Price Move, Forecast, and Earnings pages.
- Explore Trending AI Robots for AI-driven market analysis across thousands of stocks and ETFs.
Analyst Price Targets and Consensus View
OrthoPediatrics Corp. (KIDS), a Warsaw, Indiana-based medical device maker focused exclusively on pediatric orthopedics, is covered by eight analysts with a consensus rating of Buy. Their individual 12-month price targets range from a low of $27 (Stifel) to a high of $38 (Lake Street), with an overall mean of approximately $30.75. Because that mean sits essentially at or below the latest share price, it fails to provide a meaningful upside target.
Applying a minimum-distance standard, only two of the eight targets remain above the current price: $35 and $38. Their average is $36.50, rounded to $37, which serves as the central target for this analysis. This is the average of analyst targets above the current price, not an official consensus; the full average of all eight targets ($30.75) and the complete range ($27–$38) are provided for context. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Views differ sharply. Hold-rated Truist argues the stock trades at a valuation premium versus peers that already reflects its growth and emerging profitability. More bullish firms such as TD Cowen, Canaccord, Piper Sandler, BTIG, and Lake Street point to strong top-line momentum, new product contributions, and a multi-year growth runway. Recent actions have been broadly positive, with several firms raising targets after third-quarter results.
Current Market Position and Path Toward the Target
Shares of KIDS recently closed near $30.87, just below a 52-week high around $32.62, after a powerful multi-month rally. Reaching the $37 central target would require a rise of roughly 20%, a substantial move from current levels.
The path is supported by fundamental momentum: third-quarter 2026 revenue of $72.7 million rose 19% year over year, and management raised full-year revenue guidance to $270–$273 million, implying 14–16% growth. Adjusted EBITDA reached a record $6.9 million, and free cash flow turned positive. Still, the company remains unprofitable on a GAAP basis, posting a net loss of $5.9 million, or $0.25 per share, in the quarter.
What Could Support a Move Toward the Target
Several factors could support a continued advance. OrthoPediatrics is in what management calls an innovation "Super Cycle," with new products such as the 3P Hip plating system, Traxio, and VerteGlide beginning to contribute revenue. Its specialty bracing franchise (OPSB) grew more than 20%, with over 60 clinics and 34 product systems. International revenue rose 18%, aided by new European launches following regulatory approvals.
Critically, the company is improving its financial profile: 74% gross margins, record adjusted EBITDA, positive free cash flow, and guidance for breakeven free cash flow in 2026 and positive free cash flow in 2027. Analyst revisions have been mostly upward, and consensus sentiment remains Buy.
What Could Prevent the Target From Being Reached
The principal obstacle is valuation. The stock's sharp run — roughly a 91% one-year gain — has outpaced analyst targets, leaving the broader sell-side mean below the current price. Persistent GAAP net losses and an EPS that remains negative mean the stock is still priced on growth expectations rather than current profitability.
Other risks include margin pressure from the lower-margin bracing business, elevated sales and marketing spending (up 24% year over year), foreign-exchange and Latin America set-sales headwinds, and the inherent uncertainty of commercializing many new products simultaneously. If execution slips or multiple expansion stalls, the stock could consolidate well short of $37.
Technical Levels and Market Structure
From a technical standpoint, KIDS trades just under its 52-week high near $32.62, which now acts as the immediate resistance level. A decisive move through that area would clear a meaningful overhead milestone on the way toward the $37 target. On the downside, the pre-earnings consolidation zone near $24–$25 represents a potential support level, with the psychological $30 mark serving as nearer-term support. The long-term trend is decisively upward after recovering from a 52-week low near $14.42.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of roughly 12 months, though individual firms vary in their methodology and timeline. Investors should watch upcoming quarterly results, further full-year guidance updates, new product launch progress (including the transition from limited to full commercial release), adjusted EBITDA and free cash flow trajectory, and any additional analyst target revisions. Macroeconomic factors such as hospital procedure volumes, interest rates, and currency moves may also influence the path.
Using Tickeron’s AI Daily Buy/Sell Signals
I regularly turn to Tickeron’s AI Daily Buy/Sell Signals when evaluating names like this one. The tool applies artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals grounded in technical behavior and market conditions. For a stock where momentum and valuation are both in focus, it helps me track trend shifts and position changes more efficiently than manual review alone. Traders looking for a structured edge can incorporate these signals into their broader research process.
Final Assessment
The question of whether OrthoPediatrics (KIDS) can reach $37 hinges on whether its fundamental momentum can extend a rally that has already outpaced most analyst expectations. The $37 figure represents the average of the two analyst targets above the current price, against an overall mean of $30.75 and a range of $27 to $38. That wide dispersion underscores genuine disagreement: bulls see a multi-year product cycle driving sustained growth, while skeptics argue the valuation already reflects the optimism. Reaching $37 would require roughly a 20% advance from recent levels — substantial but not unprecedented for a stock posting 19% revenue growth and improving cash flow. Investors should monitor execution on new product launches, progress toward profitability, and whether analyst targets catch up to the share price.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
KIDS in upward trend: price rose above 50-day moving average on October 20, 2026
KIDS moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 42 of 54 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 78%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on KIDS as a result. In 60 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.
The Moving Average Convergence Divergence (MACD) for KIDS just turned positive on October 20, 2026. Looking at past instances where KIDS's MACD turned positive, the stock continued to rise in 30 of 40 cases over the following month. The odds of a continued upward trend are 75%.
The 10-day moving average for KIDS crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +32.33% 3-day Advance, the price is estimated to grow further. Considering data from situations where KIDS advanced for three days, in 215 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KIDS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
KIDS broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 16 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.346) is normal, around the industry mean (4.209). P/E Ratio (-18.375) is within average values for comparable stocks, (1.433). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (2.175) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. KIDS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KIDS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of orthopedic devices
Industry MedicalNursingServices
Advertisement